Table 3.
Characteristics of recurrent AKI patients
| Early recurrence (n=44) |
Non-recurrence or late recurrence (n=357) |
P value | |
| Age (years), median (IQR) | 54 (43–74) | 58 (51–72) | 0.316 |
| Sex (male) | 22 (50%) | 227 (64%) | 0.080 |
| Baseline SCr (mg/dL), median (IQR) | 0.95 (0.52–1.14) | 1.01 (0.79–1.15) | 0.681 |
| AKI severity (KDIGO) stage I | 32 (73%) | 243 (68%) | 0.312 |
| stage II | 9 (20%) | 60 (17%) | |
| stage III | 3 (7%) | 54 (15%) | |
| Admission to ICU at first AKI | 10 (23%) | 46 (13%) | 0.076 |
| Comorbidities Hypertension |
19 (43%) | 140 (39%) | 0.612 |
| Diabetes mellitus | 14 (32%) | 87 (24%) | 0.283 |
| Coronary artery disease | 8 (18%) | 51 (14%) | 0.491 |
| CHF | 11 (25%) | 82 (23%) | 0.763 |
| Advanced LD | 6 (14%) | 36 (10%) | 0.468 |
| Malignancy | 22 (50%) | 174 (49%) | 0.875 |
| Drug Diuretic |
31 (71%) | 143 (40%) | <0.001 |
| ACEi/ARB | 11 (25%) | 95 (27%) | 0.819 |
| Deaths after 21 st days from the first AKI | 26 (59%) | 82 (23%) | <0.001 |
II receptor blocker.
Values for continuous variables, as mean ±SD deviation.
Conversion factors for serum creatinine in mg/dL to μmol/L,×88.4.
ACEi, ACE inhibitor; AKI, acute kidney injury; ARB, angiotensin; CHF, chronic heart failure; ICU, intensive care unit; KDIGO, Kidney Disease Improving Global Outcomes; LD, liver disease; SCr, serum creatinine.